

## Available Drugs for Prescribing under Schedule 3 of the Manitoba Pharmaceutical Regulations

*\* Schedule 3 lists the prescription drug categories that a member may prescribe once authorized. The following list contains the available drugs (but not necessarily commercially available drug products) under these prescription categories.*

For the most up to date information on the list of drugs included under an Anatomical Therapeutic Chemical (ATC) code, please visit the World Health Organization ATC website [here](#). Not all drugs included in the list may be available in Canada. Pharmacists are responsible for selecting an appropriate product.

### **Atopic Dermatitis, Allergic and Irritant Contact Dermatitis, Urticaria**

D07AA: Corticosteroids, weak (group I), dermatological preparations

- Hydrocortisone
- Methylprednisolone
- Prednisolone

N.B. Combinations of corticosteroids are NOT included for weak corticosteroid dermatological preparations.

D07AB: Corticosteroids, moderately potent (group II), dermatological preparations

- |                           |                           |
|---------------------------|---------------------------|
| • Clobetasone             | • Desonide                |
| • Hydrocortisone butyrate | • Triamcinolone           |
| • Flumethasone            | • Alclometasone           |
| • Fluocortin              | • Hydrocortisone butyrate |
| • Fluperolone             | • Dexamethasone           |
| • Fluorometholone         | • Clocortolone            |
| • Fluprenidene            |                           |

N.B. Combinations of corticosteroids are included for moderately potent corticosteroid dermatological preparations.

### **Acne Vulgaris**

D10AE01: Benzoyl peroxide

D10AF01: Clindamycin

D10AF51: Clindamycin, combinations

N.B. Combination products containing benzoyl peroxide and clindamycin are included in the above category. Other clindamycin combination products cannot be prescribed by a pharmacist.

## Available Drugs for Prescribing under Schedule 3 of the Manitoba Pharmaceutical Regulations

### **Tinea Pedis**

D01AE: Other antifungals for topical use

- Butenafine
- Undecylenic acid
- Bromochlorosalicylanilide
- Methylosaniline
- Tribromometacresol
- Polynoxylin
- 2-(4-chlorphenoxy)-ethanol
- Ticlatone
- Sulbentine
- Ethyl hydroxybenzoate
- Haloprogin
- Amorolfine
- Dimazole
- Tolciclate
- Flucytosine
- Tavaborole
- Liranaftate
- Chlorphenesin
- Ciclopirox
- Naftifine
- Terbinafine
- Tolnaftate
- Salicylic acid
- Selenium sulfide
- Combinations

### **Candidal Stomatitis**

A07AA02: Nystatin

- Nystatin Oral

N.B. Combination nystatin products are not included in this category.

### **Unspecified Haemorrhoids without Complication**

C05AA: Corticosteroids for treatment of hemorrhoids and anal fissures for topical use

- Hydrocortisone
- Prednisolone
- Betamethasone
- Fluorometholone
- Fluocortolone
- Dexamethasone
- Fluocinolone acetonide
- Fluocinonide
- Triamcinolone

N.B. All antihemorrhoidal products, which contain corticosteroids, are classified in this group, including both plain products and combinations with anti-infectives, local anaesthetics etc. Combinations may occur.

**Vasomotor and Allergic Rhinitis**

R01AD: Corticosteroid nasal preparations for topical use

- Beclomethasone Nasal
- Prednisolone Nasal
- Tixocortol Nasal
- Dexamethasone Nasal
- Flunisolide Nasal
- Budesonide Nasal
- Fluticasone Nasal
- Betamethasone Nasal
- Mometasone Nasal
- Triamcinolone Nasal
- Fluticasone furoate Nasal
- Ciclesonide Nasal
- Fluticasone, combinations
- Mometasone, combinations

N.B. Combinations of corticosteroid nasal preparations for topical use are included for mometasone, prednisolone, dexamethasone, fluticasone, and hydrocortisone.

R01AX03: Ipratropium Bromide Nasal

**Seborrhoeic Dermatitis (Excluding Pediatric)**

D01AE: Other antifungals for topical use

- Butenafine
- Undecylenic acid
- Bromochlorosalicylanilide
- Methylrosaniline
- Tribromometacresol
- Polynoxylin
- 2-(4-chlorphenoxy)-ethanol
- Ticlatone
- Sulbentine
- Ethyl hydroxybenzoate
- Haloprogin
- Amorolfine
- Dimazole
- Tolciclate
- Flucytosine
- Tavaborole
- Liranaftate
- Chlorphenesin
- Ciclopirox
- Naftifine
- Terbinafine
- Tolnaftate
- Salicylic acid
- Selenium sulfide
- Combinations

N.B. Combined preparations are classified in this group if mycosis is the main indication. As well, combined preparations containing salicylic acid, which are used as antifungals (e.g. dusting powders), are included.

## **Available Drugs for Prescribing under Schedule 3 of the Manitoba Pharmaceutical Regulations**

### **Recurrent Oral Aphthae**

A01AC: Corticosteroids for local oral treatment (stomatological preparations)

- Triamcinolone
- Dexamethasone
- Hydrocortisone
- Prednisolone
- Prednisolone, combinations

N.B. Combinations of corticosteroids and local anesthetics are classified here for local oral treatment.

### **Vomiting of Pregnancy, Unspecified**

R06AA59: Doxylamine, Combinations

N.B. Combination products with doxylamine are included in the above category.

### **Smoking Cessation**

N07BA: Drugs used in nicotine dependence

- Nicotine Sublingual/buccal
- Nicotine Chewing gum
- Nicotine Nasal
- Nicotine Inhalation
- Nicotine Transdermal
- Varenicline

N.B. Bupropion is not included in this category.

*End of document*

Updated October 2023